DBV Technologies (NASDAQ:DBVT) Shares Pass Below 50 Day Moving Average – Time to Sell?

DBV Technologies S.A. (NASDAQ:DBVT)’s share price passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $18.77 and traded as low as $15.69. DBV Technologies shares last traded at $16.11, with a volume of 376,501 shares trading hands.

Analysts Set New Price Targets

A number of equities analysts have weighed in on DBVT shares. Wall Street Zen raised DBV Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Guggenheim reiterated a “buy” rating and issued a $51.00 price objective on shares of DBV Technologies in a report on Monday, May 4th. Citizens Jmp boosted their price objective on shares of DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Friday, May 1st. Finally, Citigroup restated an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $48.50.

DBV Technologies Price Performance

The firm has a market capitalization of $948.54 million, a P/E ratio of -3.59 and a beta of -0.99. The firm’s 50 day moving average is $18.53 and its two-hundred day moving average is $19.87.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.42). DBV Technologies had a negative return on equity of 129.88% and a negative net margin of 2,895.37%.The firm had revenue of $0.90 million for the quarter, compared to the consensus estimate of $1.11 million. Analysts anticipate that DBV Technologies S.A. will post -0.47 EPS for the current fiscal year.

Institutional Trading of DBV Technologies

Hedge funds and other institutional investors have recently modified their holdings of the stock. MPM Bioimpact LLC bought a new stake in DBV Technologies in the 2nd quarter valued at $9,649,000. Adage Capital Partners GP L.L.C. bought a new position in DBV Technologies in the second quarter valued at about $9,659,000. Octagon Capital Advisors LP acquired a new position in DBV Technologies during the 2nd quarter worth approximately $9,315,000. Artisan Partners Limited Partnership acquired a new position in shares of DBV Technologies during the third quarter worth $519,000. Finally, DLD Asset Management LP acquired a new position in DBV Technologies in the 3rd quarter worth about $250,000. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.